Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 17/20 | 0.57 |
| ▸ | GSK3B | P49841 | 17/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.57 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378942 | 0.83 | GSK3A (0.49) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL659375 | 0.78 | AHR (0.48) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL29550002 | 0.78 | AHR (0.48) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL15668494 | 0.76 | AHR (0.56) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL680301 | 0.75 | GSK3A (0.46) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL379385 | 0.74 | GSK3B (1.00) | GSK3AGSK3BCDK5CDK5R1CCNB2 | |
| SCHEMBL12210337 | 0.74 | TDP1 (0.45) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL10963118 | 0.73 | GSK3A (0.49) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL29606493 | 0.72 | CYP1A2 (0.50) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL1554278 | 0.72 | CYP1A2 (0.50) | GSK3AGSK3BCDK5CDK5R1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| CN-116670144-A | Tricyclic compounds and uses thereof | 南京再明医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230086933-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-03-23 | — | — | US | disclosed |
| EP-4081524-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901660-A | Substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114846015-A | Substituted heteroaryl compounds useful as T cell activators | 百时美施贵宝公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133752-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086933-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKG, DGKZ | GSK3A 548/4885GSK3B 715/4885CDK5 759/4885 |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | GSK3A 737/4885GSK3B 948/4885CDK5 578/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | GSK3A 737/4885GSK3B 948/4885CDK5 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.